1. Search Result
Search Result
Results for "

SI

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

2

Natural
Products

4

Recombinant Proteins

2

Isotope-Labeled Compounds

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117357

    SGK Cancer
    SI-113 is a SGK1 inhibitor, with an IC50 of 600 nM. SI113 induces autophagy .
    SI-113
  • HY-129603

    STAT Ligands for Target Protein for PROTAC Cancer
    SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36 .
    SI-109
  • HY-101447A

    EPH 116 hydrochloride

    Others Cancer
    SI-2 (EPH 116 hydrochloride) is a highly promising SRC-3 inhibitor (PPI), with IC50 values of 3-20 nM for breast cancer cell death. SI-2 (EPH 116 hydrochloride) has a much improved toxicity and pharmacokinetic profile, with acceptable oral availability .
    SI-2 hydrochloride
  • HY-P99676

    SI-B001

    EGFR Cancer
    Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
    Izalontamab
  • HY-139426A

    trans-ML-SI3

    TRP Channel Autophagy Cancer
    (rel)-ML-SI3 is one of the active ingredients of ML-SI3 (HY-139426) (another component is (cis)-ML-SI3) that targets three isoforms of TRPML. (rel)-ML-SI3 is an inhibitor of TRPML1 and TRPML3 (IC50=3.1 μM/28.5 μM), and a potent activator of TRPML2 (EC50=3.3 μM) .
    (rel)-ML-SI3
  • HY-139426
    ML-SI3
    1 Publications Verification

    ML-SI3 (cis/trans mix)

    Parasite TRP Channel Cardiovascular Disease Neurological Disease
    ML-SI3 is a mixture of cis/trans ML-SI3 (HY-139426A), which is a TRPML1/2 channel inhibitor with IC50s of 4.7 μM and 1.7 μM, respectively. ML-SI3 also inhibits lysosomal calcium efflux and blocks downstream TRPML1-mediated autophagy. The cis/trans ML-SI3 (HY-139426A) components of ML-SI3 are TRPML2 activators with EC50s of 3.3 μM and 9.4 μM, respectively .
    ML-SI3
  • HY-164527

    Src FAK EGFR Cancer
    Si306 is a Src inhibitor with antitumor activity. Si306 reduces the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), and inhibits the invasion of human glioblastoma (GBM) .
    Si306
  • HY-101447

    EPH 116

    Src Apoptosis Cancer
    SI-2 (EPH 116) is an inhibitor for steroid receptor coactivator-3 (SRC-3), which reduces the transcriptional activity and protein concentration of SRC-3 in cells, exhibits cytotoxicity in cancer cell, with IC50s ranging from 3-20 nM, inhibits migration of MDA-MB-468, induces apoptosis of MDA-MB-468. SI-2 inhibits the tumor growth in mouse models, without significant toxicity for heart and other major organs (20 mg/kg) .
    SI-2
  • HY-RS12889

    Small Interfering RNA (siRNA) Others

    SI Human Pre-designed siRNA Set A contains three designed siRNAs for SI gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SI Human Pre-designed siRNA Set A
    SI Human Pre-designed siRNA Set A
  • HY-150927

    Ras Cancer
    G12Si-2, an analog of G12Si-1 (HY-150926), is a negative control tool. G12Si-2 is not a covalent inhibitor of the G12S mutant of K-Ras .
    G12Si-2
  • HY-150926

    Ras Cancer
    G12Si-1 is a selective K-Ras(G12S) covalent inhibitor, which can inhibit oncogenic signaling of K-Ras(G12S). G12Si-1 shows good ability to covalently engage recombinant K-Ras(G12S) at the mutant serine residue. G12Si-1 can also affect nucleotide cycling of K-Ras by blocking Sos-catalyzed exchange and decreasing the rate of EDTA promoted exchange .
    G12Si-1
  • HY-131721

    Others Others
    14,15-EET-SI is a sulfonimide (SI) analog metabolized from 14,15-EET, which is also an effective mitogen. 14,15-EET-SI can stimulate the incorporation of [3H] thymidine, activate pp60c-src and initiate the tyrosine kinase cascade, mediating their mitotic effects. Additionally, 14,15-EET-SI can increase cell proliferation as well as the expression of c-fos and egr-1 mRNA .
    14,15-EET-SI
  • HY-121582

    (E)-EPH 116

    Others Cancer
    (E)-SI-2 is an isomer of SI-2, an inhibitor of the steroid receptor coactivator SRC-3. SI-2 has anticancer activity and increases the number of cytotoxic immune cells in mice with breast cancer .
    (E)-SI-2
  • HY-134819A

    (-)-trans-ML-SI3

    TRP Channel Neurological Disease
    (1R,2R)-ML-SI3 is an isomer of ML-SI3 and a potent inhibitor of three isoforms of TRPML. (1R,2R)-ML-SI3 inhibits TRPMLs with IC50s of 1.6 μM (TRPML1), 2.3 μM (TRPML2), and 12.5 μM (TRPML3), respectively .
    (1R,2R)-ML-SI3
  • HY-134819

    (+)-trans-ML-SI3

    TRP Channel Cancer
    (1S,2S)-ML-SI3 is a trans-isomer of ML-SI3 that targets all three isoforms of TRPML. (1S,2S)-ML-SI3 is an activator of TRPML2 and TRPML3 (EC50=2.7 μM/10.8 μM) and a potent inhibitor of TRPML1 (IC50=5.9 μM) .
    (1S,2S)-ML-SI3
  • HY-134818
    ML-SI1
    5 Publications Verification

    TRP Channel Neurological Disease
    ML-SI1, a racemic mixture of diastereomers, is a TRPML inhibitor with an IC50 value of 15 μM for TRPML1 .
    ML-SI1
  • HY-109525

    Others Metabolic Disease
    Sacrosidase is a yeast-derived enzyme that facilitates sucrose digestion. Sacrosidase has the potential for congenital sucrase-isomaltase (SI) deficiency research .
    Sacrosidase
  • HY-130812

    Drug-Linker Conjugates for ADC Cancer
    Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker .
    Gemcitabine-O-Si(di-iso)-O-Mc
  • HY-163469

    Src Cancer
    SRC-3-IN-2 (SI-12 6c)is an orally active steroid receptor coactivator 3 (SRC-3) inhibitor. SRC-3-IN-2 has antitumor activity .
    SRC-3-IN-2
  • HY-137498

    Filovirus Infection
    EBOV/MARV-IN-1 is a potent inhibitor of Ebola virus (EBOV) and Marburg virus (MARV), with broad-spectrum activity (EC50=0.31, and 0.82 µM, respectively) and low cytotoxicity (SI>100) in HeLa cells .
    EBOV/MARV-IN-1
  • HY-W026467

    Parasite Infection
    MMV665916, a quinazolinedione derivative, is an antimalarial agent. MMV665916 displays antiplasmodial activity against P. falciparum FcB1 strain with EC50 value of 0.4 µM and presents the high selectivity index (SI>250) .
    MMV665916
  • HY-115989

    HCV Infection
    HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC50=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile .
    HCV-IN-38
  • HY-139218

    E3 Ligase Ligand-Linker Conjugates Others
    (S,R,S)-AHPC-Me-C6-NH2 can be used for the synthesis of PROTAC . (S,R,S)-AHPC-Me-C6-NH2 (Compound SI-9) contains VHL ligand 2 (HY-112078) .
    (S,R,S)-AHPC-Me-C6-NH2
  • HY-150554

    Bacterial Infection
    Antitubercular agent-29 (compound 6xa) is a potent agent resistant (DR) Mycobacterium tuberculosis (Mtb) inhibitor with MIC of 0.03 μg/mL against agent-susceptible (DS)-Mtb strains, MIC of 0.03-0.06 μg/mL against DR-Mtb strains, and favourable selectivity (SI>40) against Vero cells .
    Antitubercular agent-29
  • HY-151174

    Phosphodiesterase (PDE) Inflammation/Immunology
    PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC50s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .
    PDE4-IN-12
  • HY-115929

    DNA/RNA Synthesis Infection
    DENV-IN-4 is a potent DENV inhibitor (DENV EC50=4.79 μM, Vero CC50>100 μM, SI>20.9). DENV-IN-4 can inhibit the expression level of DENV2 with concentration-dependence and reduce RNA-dependent RNA polymerase (RdRp) enzymatic activity. DENV-IN-4 has antiviral effect .
    DENV-IN-4
  • HY-163468

    Src Cancer
    SRC-3-IN-1 (compound SI-10) is a steroid receptor coactivator 3 (SRC-3) inhibitor (IC50=3.3 μM). SRC-3-IN-1 has good water solubility, oral bioavailability, and improved selectivity profile. SRC-3-IN-1 can be used in prostate cancer research .
    SRC-3-IN-1
  • HY-151612

    Parasite Infection
    Anti-infective agent 6 (compound 28) is a potent anti-infectious agent. Anti-infective agent 6 shows a good activity against P. falciparum F32-ART (IC50=1.4 μM) with a good selectivity index (SI>36). Anti-infective agent 6 also shows a potency against L. donovani (IC50=3.5 μM) .
    Anti-infective agent 6
  • HY-162833

    Parasite Infection
    Antileishmanial agent-30 (compound 17k) is a potent inhibitor of leishmania, with the IC50, CC50, and SI of 0.2 μM, >100 μM and >500 for L. donovani .
    Antileishmanial agent-30
  • HY-130818

    ADC Linker Cancer
    N-(5-Hydroxypentyl)maleimide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as Gemcitabine-O-Si(di-iso)-O-Mc (HY-130812) ) .
    N-(5-Hydroxypentyl)maleimide
  • HY-139845

    HIV Infection
    Antiviral agent 9 reaches a single-digit picomolar EC50 value (0.006 nM) against HIV-1 and nearly 300-fold higher selectivity index (SI) compared to tenofovir alafenamide fumarate (TAF).
    Antiviral agent 9
  • HY-N10564

    P-glycoprotein Cancer
    8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits P-gp activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .
    8α,9α-Epoxycoleon-U-quinone
  • HY-B0389S20

    Glucose-13C,d-1; D-(+)-Glucose-13C,d-1; Dextrose-13C,d-1

    Endogenous Metabolite Metabolic Disease Cancer
    D-Glucose- 13C,d-1 is the deuterium and 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical si
    D-Glucose-13C,d-1
  • HY-121914

    o-Chlorotriphenylmethanol

    Calcium Channel Neurological Disease
    (2-Chlorophenyl)diphenylmethanol (UCL 1880) is an analog of the metabolite 2-chlorophen-diphenyl-methanol (CBM) of 2-chlorophenyl, The IC50 for sI(AHP) inhibition is 1-2 μM. (2-chlorophenyl)diphenylmethanol is a weak Ca 2+ channel blocker .
    (2-Chlorophenyl)diphenylmethanol
  • HY-B0389S22

    Glucose-13C2,d2; D-(+)-Glucose-13C2,d2; Dextrose-13C2,d2

    Endogenous Metabolite Metabolic Disease Cancer
    D-Glucose- 13C2,d2 is the deuterium and 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical si
    D-Glucose-13C2,d2
  • HY-146815

    Histamine Receptor Filovirus Infection
    CP19, a histamine receptor antagonist, is an entry inhibitor against both Ebolavirus (EBOV) and Marburgvirus (MARV) with IC50s of 3.4 μM and 29.5 μM, respectively. CP19 has SI values of 29.4 and 3.4 for EBOV and MARV, respectively. CP19 has antiviral activity .
    CP19
  • HY-129602
    SD-36
    5 Publications Verification

    PROTACs STAT Apoptosis Cancer
    SD-36 is a potent and efficacious STAT3 PROTAC degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase . SD-36 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    SD-36
  • HY-121914R

    Calcium Channel Neurological Disease
    (2-Chlorophenyl)diphenylmethanol (Standard) is the analytical standard of (2-Chlorophenyl)diphenylmethanol. This product is intended for research and analytical applications. (2-Chlorophenyl)diphenylmethanol (UCL 1880) is an analog of the metabolite 2-chlorophen-diphenyl-methanol (CBM) of 2-chlorophenyl, The IC50 for sI(AHP) inhibition is 1-2 μM. (2-chlorophenyl)diphenylmethanol is a weak Ca2+ channel blocker .
    (2-Chlorophenyl)diphenylmethanol (Standard)
  • HY-121537

    COX Akt Apoptosis Neurological Disease Inflammation/Immunology Cancer
    CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities .
    CAY10404
  • HY-D0175
    3-Aminopropyltriethoxysilane
    1 Publications Verification

    γ-AminopropyltriethoxySIlane; APTES

    Biochemical Assay Reagents Others
    3-Aminopropyltriethoxysilane (APTES) acts as a strong glue to immobilize biomolecules such as antibodies and enzymes to silicon and silicon derivatives such as silicon nitride (Si3N4 )) on. 3-Aminopropyltriethoxysilane also acts as a spacer, providing biomolecules with more spatial freedom during immobilization for higher specific activity. 3-Aminopropyltriethoxysilane can form a more stable, sensitive, and highly biocompatible bioanalytical platform by immobilizing biomolecules onto some solid materials, electrode materials, nanomaterials, and nanocomposites .
    3-Aminopropyltriethoxysilane
  • HY-144749

    Others Cancer
    AKR1C3-IN-5 (Compound 6e) is a potent inhibitor of AKR1C3. AKR1C3 enzyme is overexpressed in hormone-dependent prostate and breast tumors. AKR1C3-IN-5 derived from drupanin, which exhibits half-maximal inhibitory concentration (IC50) of 9.6 ± 3 μM and selectivity index (SI) of 5.5 against MCF-7 cells .
    AKR1C3-IN-5
  • HY-126247

    Ras Cancer
    BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.
    BI-2852
  • HY-126247B

    Others Cancer
    (R)-BI-2852 is the isomer of BI-2852 (HY-126247), and can be used as an experimental control. BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.
    (R)-BI-2852
  • HY-145432

    PI3K Cancer
    PI3K-IN-28 (Compound 6c) is a potent inhibitor of PI3K. PI3K-IN-28 displays the most potent activity with lower toxic effects on MCF-10a. PI3K-IN-28 displays half-maximal inhibitory concentration (IC50, μM) values of 5.8, 2.3, and 7.9. PI3K-IN-28 is the most potent one with a selectivity index (SI) of 39 and is considered as a latent lead for further optimization of anticancer agents .
    PI3K-IN-28
  • HY-119396

    Others Cancer
    DY3002 is a selective and highly potent EGFR inhibitor with activity in overcoming T790M-mediated drug resistance in non-small cell lung cancer. DY3002 exhibited superior inhibitory effects against EGFR T790M mutants in kinase assays (IC50 = 0.71 nM), compared to weaker inhibitory effects against wild-type EGFR (IC50 = 448.7 nM). DY3002 was significantly superior to rociletinib and osimertinib in selectivity, showing an extremely high selectivity index (SI = 632.0). In cell experiments, DY3002 had an IC50 value of 0.037 μM against H1975 cells, showing enhanced inhibitory potency. In addition, DY3002 was superior to other alternative compounds in terms of biological properties and did not cause hyperglycemia .
    DY3002

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: